Cambridge Healthtech Institute 第12届
第15届Discovery on Target其中一环
本会议思考重视标靶的新时代新药发现，将介绍应用G蛋白质偶联受体 (GPCR) 结构与构型相关知识，实现偏倚受体朝合适的途径传达讯号并避免经不好的途径的新药剂候补调整方法。另外也将讨论贯通细胞膜的复杂标靶Class的GPCR标靶化，分享目前研究成果、检讨各种GPCR结构研究重要成果及生物物理学技术应用对GPCR为基础的新药发现之影响。
RECOMMENDED ALL ACCESS PACKAGE:
· September 25 Symposium: Constrained Peptides and Macrocyclics
· September 25 Short Course: GPCR Structure-Based Drug Discovery
· September 26-27 Conference: GPCR-Based Drug Discovery
· September 27 Short Course: Introduction to Allosteric Modulators and Biased Ligands of GPCRs
· September 28-29 Symposium: CNS and Neurodegenerative Targets
Day 1 | Day 2
Tuesday, September 26
7:00 am Registration Open and Morning Coffee
GPCR Pharmacology and Biased Signaling
8:00 Welcome Remarks
Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute
8:05 Chairperson's Opening Remarks
Annette Gilchrist, Ph.D., Professor, Pharmacology, Midwestern University
8:10 Mechanistic Insights into Opioid Receptor Function from Molecular Dynamics Simulations
FEATURED PRESENTATION: Marta Filizola, Ph.D., Professor, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Understanding at the molecular level how to fine-tune opioid receptor signaling toward the analgesic pathway and away from those mediating adverse effects is essential for the future discovery of improved opioid-based painkillers for the management of acute and/or chronic pain. I will provide an overview of studies we are carrying out to address this problem using enhanced molecular dynamics simulation strategies and cutting-edge statistical analyses.
8:40 Biased Signaling at µ Opioid Receptor Splice Variants
Ying-Xian Pan, M.D., Ph.D., Laboratory Head, Department of Neurology, Memorial Sloan Kettering Cancer Center
Extensive 3' alternative splicing of the µ opioid receptor gene (OPRM1) creates multiple C-terminal splice variants that are potentially subjected to biased signaling. We now demonstrate in vitro that several µ agonists display differential β-arrestin 2 or G protein bias against a number of Oprm1 C-terminal splice variants, which correlates with in vivo data using targeted mouse models, providing new insights on GPCR-biased signaling.
9:10 High Resolution Crystal Structure of the Apelin Receptor
Liaoyuan Hu, Ph.D., Scientific Director, Head of Pharmacology, Amgen Asia R&D Center
The apelin receptor (APJ) plays an important role in a wide range of physiological functions and is a potential target for the treatment of a variety diseases. Here we report the high resolution co-crystal structure of APJ in complex with a surrogate peptide agonist. Overall structural features of the complex and detailed peptide/receptor interactions will be discussed.
9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing
GPCR Pharmacology and Biased Signaling (Cont.)
10:25 Ozanimod: An S1P1,5R Modulator that Causes Receptor Internalization Resulting in Altered Lymphocyte Trafficking and Amelioration of Inflammation
Julie Selkirk, Ph.D., Associate Director of Biology, Receptos/Celgene
S1P1R is a GPCR expressed on lymphocytes mediating migration out of secondary lymphoid tissues. S1P1R modulators internalize the receptor, sequestering lymphocytes and preventing their migration to inflammation sites. The S1P1,5R modulator ozanimod is in clinical development to treat Multiple Sclerosis and Inflammatory Bowel Disease. This presentation will cover the pharmacological tools we used to identify a safe and effective S1P1,5R modulator and evidence that ozanimod utilizes different residues than FTY720-p in the orthosteric ligand binding pocket.
10:55 Structure of a Family A GPCR with Synthetic Ligands Bound
Adam Weinglass, Ph.D., Director, Screening & Compound Profiling, Merck & Co.
Agonists of GPR40 enhance glucose-dependent insulin secretion and represent a potential mechanism for the treatment of type 2 diabetes mellitus. Pharmacologic studies indicate that partial and full allosteric agonists (AgoPAMs) bind distinct sites on GPR40 eliciting differentiated preclinical efficacy. Here, we present the path to a ternary complex structure with partial and full allosteric agonists bound, and evidence supporting an identified novel, lipid-facing AgoPAM binding pocket.
11:25 Biased and Cell-Specific Agonists of the Heart Disease Target, RXFP1, a Peptide-Targeted GPCR
Ross Bathgate, Ph.D., Head, Neuropeptides Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne
This presentation will discuss peptide mimetic and small molecule development at a complex peptide GPCR, the heart disease target, RXFP1. We have developed a relaxin peptide mimetic with a cell-specific signaling profile and demonstrated that an RXFP1 small molecule agonist is an allosteric biased agonist. This highlights the need to screen GPCR targeted small molecules or biologics in relevant native cell systems for biased and cell-specific signaling.
11:55 Imipridones: A New Class of Anti-Cancer Small Molecules that Selectively Engage GPCRs
Varun Prabhu, Ph.D., Associate Director, Research & Development, Oncoceutics, Inc.
GPCRs are the most commonly exploited target in modern medicine; however, efforts in oncology have been limited. We describe imipridone small molecules with a unique tri-heterocyclic core structure that selectively target GPCRs. Lead candidates were profiled using the DiscoverX GPCR platform and characterized for mechanism of action and anti-cancer efficacy.
12:10 pm Sponsored Presentation (Opportunity Available)
12:25 Session Break
12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
GPCRs in Cancer and Other Diseases
1:50 Chairperson's Remarks
Sid Topiol, Ph.D., CSO, 3D-2drug, LLC; Professor and Director, Structural and Computational Drug Discovery, Stevens Institute of Technology
1:55 GPCRs in Immune Evasion of Cancer
Tillmann Michels, Ph.D., Head of Research Group Immune Checkpoint Inhibitors, Laboratory of Phillipp Beckhove, Interventional Immunology, Regensburg Center for Interventional Immunology
Checkpoint blockade has become an important pillar of cancer therapy. We identified GPCRs and their associated signaling as immune inhibitory pathways using high throughput RNAi screening. GPCRs could either affect T cell activity directly by binding or indirectly by altering the balance of tumor-intrinsic Gα signaling. For example, cAMP can be transported into TILs and induce an inhibitory pathway resulting in TCR-associated Lck inhibition.
2:25 Phenotypic Discovery of ONC201 as the First Selective DRD2 Antagonist for Clinical Oncology
Joshua Allen, Ph.D., Vice President, R&D, Oncoceutics
Imipridones are a new class of anti-cancer small molecules that share a unique tri-heterocyclic core structure and selectively engage GPCRs. Experimental GPCR profiling revealed imipridone ONC212 selectively targets orphan GPCR GPR132/G2A at nanomolar concentrations. GPR132 is a stress-inducible orphan GPCR with highest expression in leukemia and shown to be a tumor suppressor in the context of lymphoid leukemogenesis. ONC212 was non-toxic to normal cells at therapeutic concentrations and demonstrated robust in vivo safety/efficacy in leukemia xenograft
2:55 Present and Future Collaborative Innovations within Drug Discovery Informatics
Charlie Weatherall, Director, Customer Engagement, Collaborative Drug Discovery
The CDD Vault platform (Activity & Registration, Visualization, Inventory, & ELN) provides an easy, secure way for the collaborative sharing of research data and workflows. Web-based platforms are a natural fit for collaborations due to the economic and design benefits of a single platform that transcends any one organization's requirements.
3:10 3DM Protein-Family Analysis Platform Applied to the GPCR Protein-Family
Henk-Jan Joosten, Ph.D., CEO, Bio-Prodict
Vast amounts of data are available for protein-families (e.g., sequences, literature, structural-, alignment-, SNP-, mutation-, patent-, binding data). 3DM, a protein-superfamily analysis platform, automatically collects and integrates all data and contains many state-of-the-art analysis tools. 3DM is used by many companies, including large pharma, to guide structure-based drug design.
3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced
GPCRs in Cancer and Other Diseases (Cont.)
4:05 The Apelin Receptor: Modulating Ligand Structure to Bias Signaling and Impacts on Acute Cardiac Dysfunction
Eric Marsault, University of Sherbrooke
4:35 Development of GIP Receptor Antagonists to Reveal the Role of GIP in Physiology and Pathophysiological Conditions Like Obesity and T2D
Mette M. Rosenkilde, M.D., Ph.D., Professor, Department of Biomedical Sciences, University of Copenhagen
I will discuss the incretins (that bind to class B GPCRs) and novel data for the production of a GIPR (glucose-dependent insulinotropic polypeptide receptor) antagonist for the treatment of T2D and obesity. I will also compare the action of GIP with that of the other famous incretin hormone, GLP1, for which several therapies have been launched recently.
5:05 Interactive Breakout Discussion Groups
Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.
6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)
7:10 Close of Day
Day 1 | Day 2
Wednesday, September 27
7:30 am Registration Open and Morning Coffee
Structural And Biophysical Approaches For GPCRs
8:00 Chairperson's Remarks
Andrew Alt, Ph.D., Associate Director, Biology, Arvinas
8:05 Crystal Structure of the GLP-1 Receptor Extracellular Domain in Complex with Exendin-4 and a Nanobody
Xiaomin Chen, Ph.D., Senior Principal Scientist, Structural & Molecular Sciences, Worldwide Research & Development, Pfizer
Glucagon-like peptide 1 receptor is one of the class B GPCR and an important drug target. It has an extracellular domain (ECD) in addition to the seven-transmembrane helices and the primary role of the ECD is to bind to a peptide ligand to position it so that its N-terminus binds to the transmembrane region for its activation. Here we report the crystal structure of the receptor ECD bound to exendin-4 and a nanobody.
8:35 Picking the High-Hanging Fruit: Measuring Biomolecular Interactions of GPCRs Using a Variety of Biophysical Techniques
Phillip Schwartz, Ph.D., Senior Scientist, Structural Biology and Biophysics, Takeda California
Drug discovery efforts are undergoing a renaissance in GPCR-related research as orphan receptors become de-masked and our understanding of how to study these difficult targets improves. Identifying preparations amenable to biophysical characterization is a critical step in pursuing GPCR drug development.
9:05 Presentation to be Announced
9:35 Coffee Break in the Exhibit Hall with Poster Viewing
Structural and Biophysical Approaches for GPCRs (Cont.)
10:20 NMR Spectroscopy and Integrative Structural Biology of Human GPCRs
Matthew Eddy, Ph.D., Postdoctoral Fellow, Laboratory of Raymond Stevens, The Bridge Institute, University of Southern California
Nuclear magnetic resonance (NMR) spectroscopy complements other structural biology techniques, such as x-ray diffraction, by identifying multiple simultaneously populated conformations in equilibrium. Here, we leverage this advantage to study two human GPCRs. First, we report how a GPCR fusion strategy used for x-ray crystallography influences the protein conformational equilibrium and highlight potential cases where drug-ligand interactions can be affected. Second, we report a novel approach to incorporation of stable isotopic NMR labels into a wild type human GPCR and new insights obtained from this method.
10:50 Next Generation Bio-Sensing: New Opportunities for Challenging Targets
Tim Kaminski, Ph.D., Postdoctoral Fellow, Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca Gothenburg
Single molecule experiments enable us, next to its unmatched sensitivity, to directly gain a mechanistic insight into biological processes by observing its stochastic behavior. We are developing a toolbox which advances single molecule microscopy from a method primarily used in academia into a versatile tool for drug discovery. By using this method, we are able to address shortcomings of established biophysical methods as e.g. tight binding limit, working with membrane proteins, higher throughput. Additionally, we are able to extract kinetic profiling of inhibition reactions in solution by observing the association and dissociation of thousands of molecules in parallel with a surface-based single molecule platform.
11:20 Enjoy Lunch on Your Own
12:20 pm Plenary Keynote Program
(click here for details)
2:00 Refreshment Break in the Exhibit Hall with Poster Viewing
2:45 Close of Conference